NDC product
Leader Olopatadine Hydrochloride Ophthalmic Solution
NDC 70000-0717 · CARDINAL HEALTH
Key facts
| Product NDC | 70000-0717 |
|---|---|
| Proprietary name | Leader Olopatadine Hydrochloride Ophthalmic Solution |
| Nonproprietary name | Olopatadine Hydrochloride Ophthalmic Solution |
| Substances | OLOPATADINE HYDROCHLORIDE |
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Labeler | CARDINAL HEALTH |
| Product type | HUMAN OTC DRUG |
| Marketing category | ANDA |
| Application number | ANDA206046 |
| Pharmacologic classes | Decreased Histamine Release [PE], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], Histamine-1 Receptor Inhibitor [EPC], Mast Cell Stabilizer [EPC] |
| Marketing start | Apr 15, 2025 |
| Marketing end | Jul 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory